Startseite CYP 2C19 and UDP-glucuronosyltransferases not only for drugs but also for endobiotics
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

CYP 2C19 and UDP-glucuronosyltransferases not only for drugs but also for endobiotics

  • Gérard Siest EMAIL logo , Sylvie Fournel-Gigleux und Jacques Magdalou
Veröffentlicht/Copyright: 1. November 2014
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Drug Metabolism and Drug Interactions
Aus der Zeitschrift Drug Metabolism and Drug Interactions Band 29 Heft 4

Published Online: 2014-11-1
Published in Print: 2014-12-1

©2014 by De Gruyter

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. CYP 2C19 and UDP-glucuronosyltransferases not only for drugs but also for endobiotics
  4. Review
  5. Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy
  6. Reviews in Population Pharmacogenomics
  7. Pharmacogenetics in Jewish populations
  8. Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance
  9. Original Articles
  10. Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors
  11. Effect of silymarin pretreatment on the bioavailability of domperidone in healthy human volunteers
  12. In vitro inhibitory effects of herbal supplements on tamoxifen and irinotecan metabolism
  13. Acknowledgment
  14. Acknowledgment
https://doi.org/10.1515/dmdi-2014-0030

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. CYP 2C19 and UDP-glucuronosyltransferases not only for drugs but also for endobiotics
  4. Review
  5. Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy
  6. Reviews in Population Pharmacogenomics
  7. Pharmacogenetics in Jewish populations
  8. Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance
  9. Original Articles
  10. Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors
  11. Effect of silymarin pretreatment on the bioavailability of domperidone in healthy human volunteers
  12. In vitro inhibitory effects of herbal supplements on tamoxifen and irinotecan metabolism
  13. Acknowledgment
  14. Acknowledgment
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 29.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/dmdi-2014-0030/html
Button zum nach oben scrollen